ICU耐药G+球菌感染挑战和斯沃在中国的使用病例汇总

《ICU耐药G+球菌感染挑战和斯沃在中国的使用病例汇总》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、ICU耐药G+球菌感染------挑战与策略Evaluationonly.CreatedwithAspose.Slidesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-2011AsposePtyLtd.EPICII(May8,2007)(Countries76,Ceters1265,Pats14414)55.3%50.1%38.6%70.4%50.8%71.6%49.3%58.3%50.9%57.9%33.3%74.5%52.9%56.6%TypeofmicroorganismG+/G-47%/62%Evaluationonly

2、.CreatedwithAspose.Slidesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-2011AsposePtyLtd.FromWanghui,PUMChospEvaluationonly.CreatedwithAspose.Slidesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-2011AsposePtyLtd.治疗MRSA感染的药物经典药物VancomycinTeicoplanin传统药物Trimethoprim-sulfamethoxazoleFluoroquinolon

3、esErythromycinClindamycinRifampinAminoglycosidesTetracyclinesDrewRH.Pharmacotherapy2007;27:227-49.Evaluationonly.CreatedwithAspose.Slidesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-2011AsposePtyLtd.CausesofGlycopeptideTreatmentProblemHighdensityinfectionsDeep-seatedabscess,prostheticdevic

4、einfection,infectiveendocarditis(biofilmdisease)SuboptimaldosageTroughvancomycinlevel:5-10or≥15g/mLToleranceDecreasedsusceptibilitySmallcolonyvarianthVISA,VISA,VRSA,agr(accessorygeneregulator)polymorphismEvaluationonly.CreatedwithAspose.Slidesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-20

5、11AsposePtyLtd.新型治疗MRSA的抗生素MIcekSTetal.ClinInfectDis2007;45:S184-90.Evaluationonly.CreatedwithAspose.Slidesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-2011AsposePtyLtd.斯沃的适应症医院内获得性肺炎(HAP)及社区获得性肺炎(CAP)及并发的菌血症复杂性皮肤和皮肤软组织感染非复杂性皮肤和皮肤软组织感染耐万古霉素屎肠球菌感染(包括伴发的菌血症)Evaluationonly.CreatedwithAspose.Sl

6、idesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-2011AsposePtyLtd.社区获得性肺炎院内肺炎复杂性皮肤和皮肤软组织感染糖尿病足感染菌血症MRSA所致皮肤和皮肤软组织感染VRE感染儿童患者DrugSafety2008;31:753-68.Evaluationonly.CreatedwithAspose.Slidesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-2011AsposePtyLtd.利奈唑胺优于对照药CAPNo(?atypicals)NP(MRSA,VAP)Yes

7、SSTIs(MRSA)YesDFIYes(ifMRSA,S.galactiae)BacteremiaYesVREInfectionsYesDrugSafety2008;31:753-68.Evaluationonly.CreatedwithAspose.Slidesfor.NET3.5ClientProfile5.2.0.0.Copyright2004-2011AsposePtyLtd.斯沃中国临床用药经验总结2007年斯沃(利奈唑胺)国内上市汇总分析数据来源于自上市开始到2008年10月30日全国90